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Objectives: To determine the incidence of symptomatic moderate-to-severe adverse events during treatment of
drug-resistant tuberculosis, and to compare their risk and outcomes by patients’ human immunodeficiency virus
(HIV) co-infection status.
Methods: We conducted a retrospective cohort analysis of patients treated for drug-resistant tuberculosis between
January 2008 and February 2010. Routinely, clinicians monitored and managed patients’ response to treatment until
its completion. Any symptomatic adverse event observed by the clinician or reported by the patient was recorded
in the standard patient treatment booklet of the National Tuberculosis and Leprosy Programme. There were 18
symptomatic adverse events routinely monitored. Depending on the nature of the medical intervention needed,
each was graded as mild, moderate or severe. Data were extracted from the patient treatment booklet using a
structured form, then descriptive, bivariate and Cox proportional hazard analysis performed, stratified by patients’
HIV infection status. Statistical associations were done at the 5% level of significance and reported with 95%
confidence intervals.
Results: Fifty seven (57) patients with drug-resistant tuberculosis were identified, 31 (53%) of whom were HIV
co-infected. The cumulative incidence of moderate-to-severe adverse events was 46 events in 100 patients. HIV
co-infected patients experienced more moderate-to-severe adverse events compared with the HIV uninfected
patients (median 3 versus 1 events, p = 0.01). They had a four-fold increase in the cumulative hazard of moderate-
to-severe adverse events compared with the HIV uninfected patients (HR = 4.0, 95% CI 1.5 – 10.5). Moderate-to-
severe adverse events were the main determinant of a clinician’s decision to reduce the dose or to stop the
suspected offending medicine (RR = 3.8, 95% 1.2-11.8).
Conclusions: Moderate-to-severe adverse events are common during drug-resistant tuberculosis therapy. They are
more likely to occur and to persist in HIV co-infected patients than in HIV uninfected patients. Clinicians should
employ various strategies for preventing drug-induced patient discomfort and harm, such as reducing the dose or
stopping the suspected offending medicine. Managers of tuberculosis control programmes should strengthen
pharmacovigilance systems. We recommend a more powered study for conclusive risk-factor analysis.
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The burden of tuberculosis (TB) disease in Namibia
remains high, with a case notification rate of 545 cases
per 100,000 population in 2012 [1]. The prevalence of
drug-resistant tuberculosis (DR-TB) in the country, esti-
mated at 20.1 cases per 100,000 TB patients, combined
with the high human immunodeficiency virus (HIV) co-
infection rate of about 50%, is a major public health
concern for the National Tuberculosis and Leprosy
Programme (NTLP) [1].
Both DR-TB and HIV infections need to be treated,
otherwise, the patient may not survive for too long [2,3].
The adverse effects of second-line anti-tuberculosis and
antiretroviral medicines pose a unique challenge in the
combined treatment of the two infections [2,3]. Moderate-
to-severe adverse events can cause patients’ intolerance to
second-line anti-tuberculosis medicines and antiretroviral
medicines, possibly compromising DR-TB and HIV treat-
ment outcomes. Such intolerance may require the clin-
ician treating the patient to make specific medicine dosage
adjustments, regimen changes or stop the treatment [4,5].
Similarly, treatment of HIV with highly active antiretro-
viral therapy (HAART) is associated with various adverse
effects, some of which may overlap with those of second-
line anti-tuberculosis medicines [2,3,6].
This paper is the third and last of a series of papers
[7,8] that we have published based on a dataset on the
occurrence of adverse events during treatment of DR-TB
in Namibia, each paper addressing a different aspect of
the adverse events epidemiology. The first paper de-
scribed the burden of adverse events during treatment of
DR-TB, [7] while the second paper compared, by HIV
co-infection status, the risks and the risk-factors for the
commonly observed adverse events [8]. Apart from our
research highlighted above, there is limited scientific lit-
erature on the incidence, clinical management and the
outcomes of moderate-to-severe adverse events among
patients on DR-TB therapy in Namibia.
In this paper, we describe the cumulative incidence and
the actions taken by clinicians to manage the moderate-
to-severe adverse events occurring during DR-TB treat-
ment. Secondly, we compare the risk and outcomes of
these moderate-to-severe adverse events, by patients’ HIV
co-infection status.Methods
Study design
This was a retrospective observational cohort study of
consecutive patients treated for DR-TB between January
2008 and February 2010 at the Kondja DR-TB treatment
ward in the Walvis Bay District of Namibia. All the
DR-TB patients treated at this facility during the specified
period were included in the study.Setting
The study was conducted at the Kondja DR-TB treat-
ment ward, which is a 25-bed district hospital DR-TB
treatment facility serving the entire Erongo region of
Namibia. The Erongo region had the second largest
number of patients on DR-TB treatment in Namibia at
the time of the study. In this ward, patients with micro-
biologically confirmed DR-TB infection were placed on
second-line intensive phase treatment that included par-
enteral amikacin, kanamycin or capreomycin for a mini-
mum of four months, until two sputum smears and two
successive cultures turned negative [7,9]. Clinicians de-
signed individualized regimens and calculated daily
doses of each medicine based on patients’ body weight,
in accordance with the national TB treatment guidelines
published in 2006 [9]. The HIV co-infected patients were,
additionally, treated with HAART regimens that com-
prised of lamivudine in combination with either zidovu-
dine (AZT) or stavudine (d4T) and efavirenz (EFV) or
nevirapine (NVP) [9].
The susceptibility of M. tuberculosis to anti-TB medicines
was tested by the Namibia Institute of Pathology using the
liquid culture MGIT 960 system (BACTEC™ MGIT™ 960
Mycobacteria Culture System, Becton Dickinson, New
Jersey, USA) on all M. tuberculosis confirmed cultures, for
susceptibility to isoniazid, rifampicin, streptomycin and
ethambutol. All isolates of M. tuberculosis found to be re-
sistant to rifampicin or isoniazid were sent to the National
Health Laboratory Service in South Africa for testing of
resistance to kanamycin, capreomycin, amikacin, cipro-
floxacin, levofloxacin and ethionamide.
Routinely, during DR-TB treatment, patients were closely
monitored and supervised by the clinician until com-
pletion of treatment. Any clinician-observed or patient-
reported symptomatic adverse events were recorded in the
standard patient treatment booklet designed by the NTLP.
At the time of the study, the DR-TB patient treatment
booklet listed 18 symptomatic adverse events that were
routinely monitored during treatment: abdominal pain,
constipation, hearing loss (decreased hearing), depression,
diarrhoea, dizziness, fatigue, fever, headache, joint pain,
nausea, neuropathy, psychosis, rash, tinnitus, tremors,
vision changes and vomiting [9]. According to the DR-TB
patient treatment booklet (Additional file 1), the severity
of an adverse event could be classified into three grades.
Grade 1 were the mild adverse events, requiring no
medical intervention; Grade 2 were the moderate ad-
verse events, requiring palliative [or adjunctive] inter-
vention; while Grade 3 were the severe adverse events,
requiring a change in treatment or its discontinuation
[9]. Each observed adverse event was graded by the
attending clinician as mild, moderate or severe as ex-
plained above and was managed according to the sever-
ity grading.
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Ethical approval of the study protocol was obtained from
the research unit of the Ministry of Health and Social
Services of Namibia (MoHSS) – Ref 17/3/3/AP and the
Higher Degrees Committee of the University of the
Western Cape, South Africa, both of which are institu-
tional review boards.
Data collection
The lead researcher (corresponding author) collected
data from patients’ DR-TB treatment booklet using a
structured form. No personal identifiers were recorded,
to maintain the anonymity and the confidentiality of the
patients. The primary study outcome was the occurrence
of any adverse event during DR-TB treatment. The sec-
ondary outcome was the occurrence of moderate-to-
severe adverse events. Further, detailed characterization
of each moderate-to-severe adverse event was con-
ducted, which included: its description, time-to-onset,
severity grading, duration, actions taken to manage the
adverse event, and the outcome of the adverse event.
Definition of terms
In this study, DR-TB included both poly- and multidrug
resistant forms of M. tuberculosis. Poly drug-resistance was
defined as the resistance of M. tuberculosis to either isonia-
zid or rifampicin and other first-line anti-tuberculosis
medicines, while multidrug resistance was the resistance
to at least both isoniazid and rifampicin [9].
Data analysis
We limited our statistical analyses to descriptive and
univariate analysis, due to the small sample of DR-TB
patients that was realized. We couldn’t perform multi-
variable analyses because of the few degrees of freedom
of the small sample. We therefore calculated absolute
and relative frequency counts, measures of central ten-
dency (mean and median) and measures of dispersion
including range, interquartile range and standard devi-
ation. We applied two-tailed Student’s T-tests to com-
pare group differences in age and weight after testing for
normality. For non-normally distributed variables such
as the number of adverse events observed, comparisons
were made by the non-parametric Mann–Whitney/
Wilcoxon two sample test. We compared proportions
and categorical variables using the Chi-square or Fisher
exact test respectively, depending on whether or not the
expected value for a cell in the cross-tabulation was
greater than five.
Associations between exposure and outcome variables
were assessed using 2×2 contingency tables, with further
stratification by HIV infection status. In addition, Kaplan-
Meier and Cox proportional hazard analysis were per-
formed to generate hazard ratios. All the analyses weredone in Epi Info 3.4.3. (November 2007, Centers for Dis-
ease Control and Prevention, Atlanta, USA) and reported
as point estimates, 95% confidence intervals (95% CI) and
p-values. However, the Kaplan-Meier plot was drawn using
the Statistical Package for the Social Sciences (SPSS®) for
Windows, version 12.0.1 (IBM Corporation, New York,
USA). A p-value of less than 0.05 was considered to be
statistically significant. Lastly, we used Microsoft Excel®
(Microsoft office 2010, Microsoft Corporation, Redmond,
Washington State, USA) to draw charts and tables.
Results
The proportion of DR-TB patients who experienced any
adverse event was 51/57 (89%). Of these 51 patients, 26
(51%) experienced at least one moderate-to-severe ad-
verse event. A medical intervention was made to manage
the adverse event in 29 (57%) of the patients. These
medical interventions included reducing the medicine
dose or stopping the suspected offending medicine in 15
patients (29%), using other adjunctive medicines to treat
the adverse event(s) in 14 patients (27%), or completely
changing the DR-TB treatment regimen in 9 patients
(18%). There were 20/51 (39%) patients who experienced
persistent adverse events that lasted for three months or
more, while 15/51 (29%) patients were yet to recover from
their adverse events by the study end date (Figure 1).
The distribution of the patients’ demographic and clin-
ical characteristics was generally similar between the 26
DR-TB patients who experienced at least one moderate-
to-severe adverse event compared to the 25 who experi-
enced at least one mild adverse event (Table 1). However,
the HIV co-infection rate was notably higher among the
patients who experienced at least one moderate-to-severe
adverse event, compared with those who experienced only
mild adverse events (69.2% versus 40%, p = 0.04).
Overall, the DR-TB patients co-infected with HIV ex-
perienced more moderate-to-severe adverse events com-
pared with the HIV uninfected patients, with a median
of 3 adverse events versus 1 adverse event respectively
(p = 0.01), as depicted in Table 2. Eighteen of the 26 DR-TB
patients who experienced at least one moderate-to-severe
adverse event (69%), were HIV co-infected (Figure 2).
The cumulative incidence of moderate-to-severe ad-
verse events in the entire cohort was 26 events out of 57
patients (46 events in 100 patients). By comparison, the
cumulative incidence of moderate-to-severe adverse
events amongst the HIV co-infected patients was 18
events out of 28 patients (64 events in 100 patients) while
it was 8 events out of 23 patients (35 events in 100 pa-
tients) amongst the HIV uninfected patients, (p = 0.04).
In a time-to-event analysis using a Kaplan Meier curve
and Cox proportional hazards analysis, the DR-TB pa-
tients who were co-infected with HIV had a four-fold
cumulative hazard of experiencing moderate-to-severe





















(ii) Adjunctive therapy (n=14)
(iii) Regimen changed (n=9)
Adverse events lasting 
3 months (n=20)
Adverse events not 
yet resolved
(n=15)
Figure 1 Flow diagram of DR-TB treatment, occurrence and outcomes of adverse events. Legend for Figure 1: DR-TB = drug resistant tuberculosis;
HIV = Human immunodeficiency virus; AE = adverse event.
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tients (HR = 4.0, 95% CI 1.5 – 10.5, p = 0.006), Figure 3.
In terms of medicines exposure, the DR-TB patients in
our cohort were treated with individualized regimens,
based on the susceptibility of the M. tuberculosis to spe-
cific second-line anti-TB medicines. In total, the patients
were treated with 15 different second-line anti-TB medi-
cines, while the HIV infected patients were additionally
treated with HAART regimens, which consisted of lami-
vudine in combination with either zidovudine (AZT) or
stavudine (d4T) and efavirenz (EFV) or nevirapine (NVP).
None of the second-line anti-TB or antiretroviral medi-
cines was statistically significantly associated with the oc-
currence of moderate-to-severe adverse events (Table 3).
However, amikacin, ciprofloxacin and ethambutol tended
to have a much higher risk when compared with the other
second-line anti-TB medicines.
We further explored the association between the oc-
currence of moderate-to-severe adverse events, the spe-
cific medical interventions made to manage them andTable 1 Demographic and clinical characteristics of the patien
Moderate
Gender: Male, n (%)
Age: mean ± SD, yrs
Weight: mean ± SD, kg
HIV co- infection, n (%)
HAART, n (%)
Duration (days) of therapy; median (IQR)
Number of drugs in intensive phase regimen; median (IQR)
SD = standard deviation; yrs = years; kg = kilogrammes; HIV = human immunodeficie
IQR = interquartile range.their specific outcomes. From a univariate analysis on
the entire cohort, we found that moderate-to-severe ad-
verse events determined whether the clinician chose to
reduce the dose or to stop a specific DR-TB medicine,
the risk ratio (RR) for the association being 3.8 (95% CI
1.2-11.8, p = 0.01). Upon stratification to assess for con-
founding or effect modification by HIV infection status,
the association remained similar between HIV infected
and HIV uninfected patients (RR = 4.2 and RR = 4.1 re-
spectively) (Table 4).
There were HIV stratum-specific differences in the
connection between occurrence of moderate-to-severe
adverse events and those that lasted for three or more
months. The risk ratios were RR = 3.6 (95% CI 1.03-12.5,
p = 0.009) for the HIV infected sub-group versus RR = 1.9
(95% CI 0.5-7.2, p = 0.33) for the HIV uninfected one,
demonstrating effect modification by HIV infection status
(Table 4).
On the contrary, the occurrence of moderate-to-severe
adverse events was not a determinant of the clinician’sts, by adverse event severity grading
Adverse events by severity grading (N = 51)
-to-severe events (n = 26) Mild events (n = 25) P-value
16 (61.5%) 15 (60.0%) 0.91
34.1 ± 8.3 35.0 ± 10.2 0.71
51.4 ± 10.3 53.9 ± 12.3 0.45
18 (69.2%) 10 (40%) 0.04
5 (19.2%) 7 (28%) 0.46
183.5 (173–243) 185 (175.5-212) 0.81
5 (5–6) 5 (5–6) 0.61
ncy virus; HAART = highly active antiretroviral therapy; TB = tuberculosis;
Table 2 Frequency of moderate-to-severe adverse events




Adverse events HIV infected HIV uninfected
Tinnitus 9 6
Joint pain 7 0
















Total number of adverse events 58 20
Median number of adverse events 3 1




































Number of moderate-to-severe 
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Figure 2 Distribution of the number of moderate-to-severe adverse e
resistant tuberculosis.
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adverse events (RR = 1.2, 95% CI 0.5-2.7, p = 0.74) or to
change the entire DR-TB treatment regimen (RR = 0.5,
95% CI 0.2-1.8, p = 0.31) as shown in Table 4.Discussion
We found a high occurrence (89%) of any adverse event
during DR-TB treatment. Similar findings have been re-
ported elsewhere in the study by Koju et al. in Nepal
who found that 80% of patients experienced at least one
adverse event during treatment of tuberculosis [10].
Likewise, Leimane and co-researchers reported that 86%
of patients in their study in Latvia experienced an ad-
verse event, [11] while Bloss et al. reported an adverse
event frequency of 79% in the same country [12]. Also,
Shin et al., have reported that 73% of MDR-TB patients
in their Russian cohort experienced at least one adverse
event [13]. This clearly shows that second-line anti-TB
medicines are associated with a high frequency of ad-
verse events.
The cumulative incidence of moderate-to-severe ad-
verse events in our cohort was 46 events in 100 DR-TB
patients. This finding is similar to that of Lanternier
et al., who reported an incidence of severe adverse
events of 45.2 ± 11.3 per 100 person-years [14]. Such a
high incidence of moderate-to-severe adverse events is a
cause for concern for DR-TB programme managers, pa-
tients and clinicians.
In the present study, HIV co-infected DR-TB patients
experienced more moderate-to-severe adverse events
compared with the HIV uninfected patients (58 versus
20 events, p = 0.02). The HIV co-infected patients had a
four-fold risk of experiencing moderate-to-severe ad-
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Figure 3 Kaplan Meier curve of the time to the occurrence of moderate-severe adverse events, by HIV status. Legend for Figure 3:
HIV = Human immunodeficiency virus.
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have been reported by other researchers. For example, in
Lima, Peru, Chung-Delgado et al. found that HIV infec-
tion increased the risk of adverse events during TB ther-
apy by 3.45 (95% CI 1.61-7.45) [5]. Similarly, LanternierTable 3 Use of specific second-line anti-TB or antiretroviral me
















Any HAART regimen 13 (22.8%)
Zidovudine (AZT) 5 (8.8%)
Stavudine (d4T) 6 (10.5%)
Efavirenz (EFV) 10 (17.5%)
Nevirapine (NVP) 3 (5.3%)et al. found that HIV infection increased the risk of TB
treatment-associated adverse events by 3.9 (95% CI 2.1-
7.5) [14]. Therefore, we urge clinicians to be more vigilant
and to look out for potential moderate-to-severe adverse
events when treating HIV co-infected DR-TB patients.dicines and the risk of moderate-to-severe adverse events
= 57 Univariate risk ratios 95% confidence interval p-value
1.5 0.8 – 2.6 0.18
0.0 - 0.36
1.1 0.4 – 3.1 0.86
1.5 0.8 – 2.5 0.19
0 - 0.36
0.8 0.5 – 1.5 0.49
1.7 0.9 – 3.4 0.10
0.7 0.3 – 1.6 0.50
1.1 0.4 – 3.1 0.86
0.8 0.4 – 1.4 0.37
0.6 0.4 – 1.1 0.11
1.4 0.6 – 2.9 0.50
0.9 0.3 – 2.5 0.86
0.8 0.4 – 1.7 0.56
0.7 0.1 – 3.6 0.66
0.8 0.4 – 1.7 0.56
0.4 0.1 – 2.5 0.23
1.1 0.5 – 2.6 0.82
0.9 0.4 – 1.9 0.70
0.7 0.1 – 3.7 0.66
Table 4 Relationship between occurrence of moderate-to-severe AEs, medical actions to manage the AEs and their outcome
Stratified analysis
Medical actions taken to manage AEs and outcome of AEs Entire cohort analysis HIV positive stratum HIV negative stratum
Dose reduced or medicine stopped
3.8 (1.2-11.8) 4.2 (0.6-28.8) 4.1 (1.02-16.2)
p = 0.007 p = 0.09 p = 0.04
Adjunctive therapy to treat AE symptoms
1.2 (0.5-2.7) 1.1 (0.4-2.8) 0.8 (0.1-6.0)
p = 0.74 p = 0.61 p = 0.67
Regimen changed
0.5 (0.2-1.8) 0.5 (0.1-2.6) 0.6 (0.1-4.3)
p = 0.31 p = 0.37 p = 0.50
Adverse events lasting ≥ 3 months
3.1 (1.4-7.2) 3.6 (1.03-12.5) 1.9 (0.5-7.2)
p = 0.002 p = 0.009 p = 0.33
Numbers represent risk ratio (RR) point estimates, their corresponding 95% confidence intervals in brackets, and p-values; HIV = human immunodeficiency virus;
AEs = adverse events.
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enough so that appropriate measures could be taken to
mitigate them.
None of the second-line anti-TB or antiretroviral med-
icines was statistically significantly associated with the
occurrence of moderate-to-severe adverse events. This
was rather surprising as second-line anti-TB medicines
are known to elicit moderate-to-severe adverse events
[13,15]. We argue that the failure to detect any statisti-
cally significant associations may have arisen from the
low power of the study, rather than from a real bio-
logical difference in the way the medicines acted in the
patients included in our study. However, amikacin, cip-
rofloxacin and ethambutol seemed to have a much
higher risk than the other second-line anti-TB medi-
cines. These three medicines tended to be prescribed to-
gether as part of a DR-TB regimen. This observation
needs to be further investigated in a more powered and
appropriately designed study that is capable of ruling out
bias and confounding, for example, confounding by co-
medication and confounding by indication of the medi-
cines used for the treatment of DR-TB infection and
concomitant HIV infection.
The frequency of a clinician reducing the dose or stop-
ping the suspected offending medicine was 29%, while
that of completely changing the treatment regimen was
18%. These findings are comparable with those of Prasad
et al. where 21% of the patients developed major adverse
events that required stoppage or change of the offending
medicines [16]. Similarly, Bloss et al. have reported
dosage reduction in 20% of the patients treated for
MDR-TB [12]. On the other hand, Torun et al. reported
a higher rate (55%) of withdrawal or discontinuation of
second-line medicines during MDR-TB treatment [15].
As such, we advocate for clinicians to always consider
reducing the dose, discontinuing or substituting the sus-
pected offending medicine when managing moderate-to-
severe adverse events during the treatment of DR-TB.Moderate-to-severe adverse events were the main rea-
son for clinicians’ decision to either reduce the dose or
to stop a specific DR-TB medicine (RR = 3.8, 95% CI 1.2-
11.8, p = 0.01). This remained true, irrespective of the
patients’ HIV infection status. However, patients co-
infected with HIV tended to suffer more from adverse
events that lasted for three or more months (RR = 3.6,
p = 0.009) compared with the HIV uninfected patients
(RR = 1.9, p = 0.33). The reason for the longer duration of
some adverse events in HIV co-infected patients is unclear,
but we think that it could be related to the patients’ weak-
ened immune status and to the pharmacological interac-
tions between some of the anti-TB and antiretroviral
medicines [2,3]. Clinicians need to be alert that moderate-
to-severe adverse events in patients on concomitant
DR-TB and HIV treatment may potentially last for at least
three months. Such persistence of moderate-to-severe ad-
verse events could negatively impact the patients’ ability to
adhere to both treatments, possibly compromising pa-
tients’ DR-TB and HIV treatment outcomes.
Study limitations and strengths
The adverse events described in our study were symp-
tomatic and were clinician or patient-reported. The
over- or under-reporting of some of the adverse events,
especially those that require objective confirmatory tests,
may have biased the data. Furthermore, since no causal-
ity assessments were done, it was not always possible to
attribute particular adverse events to a specific medicine
at the individual patient level. Despite this limitation, we
were able to reveal the magnitude and nature of the as-
sociation between moderate-to-severe adverse events
and HIV co-infection. We were also able to elucidate on
the relationship between the occurrence of moderate-to-
severe adverse events and the various medical interven-
tions made to manage the adverse events as well as the
outcomes of these adverse events. By unravelling some
of the complexities of DR-TB treatment, this study
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DR-TB treatment, hence enriching the evidence base
upon which clinicians and TB programme managers
may use to make decisions on improving treatment of
DR-TB infection.
Conclusions
Moderate-to-severe adverse events are common during
DR-TB treatment. They are more likely to occur and to
persist in HIV co-infected patients than in HIV unin-
fected ones. Clinicians may alleviate the discomfort and
reduce the harm of such adverse events by reducing the
dose, stopping or by changing the suspected offending
medicine. Managers of TB control programs should
strengthen pharmacovigilance systems so that clinically
important adverse events could be detected early and
control or mitigation measures instituted in time, for ex-
ample, through revision of treatment guidelines. We rec-
ommend a larger study to generate more precise and
conclusive findings on the determinants of the moderate-
to-severe adverse events and the effect of the events on
DR-TB treatment outcomes and patients’ health-related
quality of life.
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